Danaher Corporation (DHR) AI Stock Analysis

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services across three primary segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers mass spectrometers, genomics equipment, lab automation, and bioprocess technologies for pharmaceutical, biopharmaceutical, food, and research institutions. The Diagnostics segment provides chemistry, immunoassay, molecular diagnostics, and pathology systems for hospitals, physician offices, and reference laboratories. Its Environmental & Applied Solutions segment delivers water analysis and treatment systems, as well as packaging design, printing, and product traceability solutions across consumer, industrial, and natural resource markets.

Danaher's revenue grew at a five-year CAGR of 2.0% between FY2020 and FY2025. After reaching $29.45B in FY2021 with a net margin of 21.8%, revenue declined 9.5% in FY2022 to $26.64B and 10.3% in FY2023 to $23.89B. In FY2024, revenue was $23.88B before rising 2.9% to $24.57B in FY2025, when net income was $3.61B and EPS reached $7.80. Gross margin remained steady at 60.9% in FY2025, while operating margin was 20.9%. Over the trailing twelve months, revenue reached $25.11B with an operating margin of 19.8% and EPS of $5.61. For the latest quarter ended June 30, 2026, quarterly revenue grew 5.5% year-over-year and quarterly earnings grew 59.7%.

As of June 30, 2026, Danaher held $4.35B in cash and short-term investments against total debt of $26.56B, resulting in net debt of $22.21B. Total assets stood at $92.37B and shareholders' equity was $52.58B, reflecting a debt-to-equity ratio of 0.51 and a current ratio of 1.65. Operating cash flow in FY2025 reached $6.42B, supporting capital expenditures of $1.16B and free cash flow of $5.26B. During FY2025, cash deployment included $3.09B in share buybacks and $878.0M in dividends paid.

Danaher trades at a trailing P/E of 40.8x and a forward P/E of 23.8x, both above the median of its S&P 500 Healthcare peers at 27.2x and 16.5x, respectively. Its enterprise value of $177.96B represents an EV-to-EBITDA multiple of 23.5x, compared to the peer median of 15.0x, and a price-to-sales ratio of 6.4x versus the peer median of 3.4x. Shares closed at $229.04 on October 16, 2026. Over the past year, Danaher returned 9.4%, trailing the S&P 500 return of 16.8%, while its five-year return of -12.0% lagged the S&P 500 return of 83.0%.

Danaher pays a quarterly dividend with an annual forward payout of $1.60 per share, yielding 0.70%. The company has paid consecutive dividends for 34 years, maintaining an annualized five-year dividend growth rate of 14.9%. In FY2025, dividend distributions totaled $878.0M, reflecting a payout ratio of 18.7%. The most recent ex-dividend date was September 30, 2026.

Of the 25 analysts covering Danaher, 17 rate it a Strong Buy, 5 rate it a Buy, and 3 rate it a Hold, with zero Sell or Strong Sell ratings. The mean price target is $244.14, representing a 6.6% premium over the last close of $229.04. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $26.35B and EPS of $8.51, representing 9.0% earnings growth. Danaher beat EPS estimates in each of the last 4 quarters, with next earnings scheduled for October 21, 2026.

This page is an AI-written research summary of Danaher Corporation (DHR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DHR income statement, DHR balance sheet, DHR key metrics, DHR analyst forecast, DHR chart. See the DHR stock overview for the latest quote and news.